

Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer

Information for the public
Published: 3 August 2022

www.nice.org.uk

Pralsetinib (Gavreto) is not normally available on the NHS for treating RET fusion-positive non-small-cell lung cancer (NSCLC) in adults who have not had a type of medicine called a RET inhibitor before.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Roy Castle Lung Cancer Foundation](#), 0333 323 7200
- [Lung Cancer Nursing UK \(LCNUK\)](#), 01675 477607
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4685-3